Status: Recruiting
A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.
An Exploratory, Single-Arm, Open-Label, Dose-Escalation Study of the Safety, Tolerability, PK, PD, and Efficacy of Anti-CD19/BCMA Universal CAR-T Therapy RD06-05 in Autoimmune Diseases (including SLE/LN, AAV/AAGN, Anti-GBM, MN, SSc, and IIM).
Participants needed: 84
Trial details
Phase: Early Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Nanjing Bioheng Biotech Co., Ltd.Updated: Oct 2, 2025Locations: 1
Eligibility criteria
Willing and able to provide written informed consent. [+21]
Severe active central nervous system (CNS) lupus, including psychosis, seizures,... [+11]